270 Vildagliptin significantly increases the risk of bullous pemphigoid: A Finnish nationwide registry study
Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease. It causes intense pruritus and blistering, which have extensive effects on patients quality of life. The incidence of BP is increasing, although it is not yet known why. In recent years, a theory has emerged that BP may be triggered by the use of dipeptidyl peptidase 4 (DPP-4) inhibitors in the treatment of diabetes. Our nationwide study was designed to investigate the association between the use of diabetes drugs (excluding insulin) and BP, by analysis of Finnish registry data for 3397 BP patients and 12941 patients with basocellular carcinoma as controls.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: O. Varpuluoma, A. F örsti, J. Jokelainen, M. Turpeinen, M. Timonen, L. Huilaja, K. Tasanen Tags: Clinical Research: Epidemiology of Skin Diseases Source Type: research
More News: Autoimmune Disease | Cancer & Oncology | Carcinoma | Dermatology | Diabetes | Endocrinology | Epidemiology | Finland Health | Insulin | Pemphigoid | Skin | Study